Vastarel 20mg

  • Name:

    Vastarel 20mg

  • Company:
    info
  • Active Ingredients:

    Trimetazidine dihydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/05/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 19/5/2020

Click on this link to Download PDF directly

Servier Laboratories Ireland Ltd

Servier Laboratories Ireland Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name ACERYCAL Active Ingredients Amlodipine besilate, Perindopril arginine
Medicine Name Coverdine Active Ingredients Amlodipine, Indapamide, Perindopril
Medicine Name Coversyl Arginine 10mg Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine 10mg orodispersible tablets Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine 5mg Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine 5mg orodispersible tablets Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine Plus 10mg/2.5mg film-coated tablets Active Ingredients Indapamide, Perindopril arginine
Medicine Name Coversyl Arginine Plus 2.5mg/0.625mg film-coated tablets Active Ingredients Indapamide, Perindopril arginine
Medicine Name Coversyl Arginine Plus 5 mg/1.25 mg film-coated tablets Active Ingredients Indapamide, Perindopril arginine
Medicine Name Diamicron MR 30 mg Active Ingredients Gliclazide
Medicine Name Diamicron MR 60mg Active Ingredients Gliclazide
Medicine Name LIPERCOSYL Active Ingredients Atorvastatin calcium trihydrate, Perindopril arginine
Medicine Name LIPOCOMB Active Ingredients ezetimibe, Rosuvastatin Calcium
Medicine Name LONSURF Active Ingredients Tipiracil hydrochloride, Trifluridine
Medicine Name Natrilix SR Active Ingredients Indapamide
Medicine Name Oncaspar 750 U/ml powder for solution for injection/infusion Active Ingredients pegaspargase
Medicine Name ONIVYDE Active Ingredients Irinotecan hydrochloride trihydrate
Medicine Name Pixuvri 29 mg Active Ingredients Pixantrone dimaleate
Medicine Name Procoralan film-coated tablets Active Ingredients Ivabradine hydrochloride
Medicine Name Valdoxan 25mg Film-coated Tablets Active Ingredients Agomelatine
Medicine Name Vastarel 20mg Active Ingredients Trimetazidine dihydrochloride
1 - 0 of 21 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19 May 2020

Reasons for updating

  • Improved presentation of SmPC

Updated on 19 May 2020 PIL

Reasons for updating

  • Change due to harmonisation of PIL

Updated on 20 November 2018 PIL

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents

Updated on 20 November 2018

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Updated on 27 June 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 26 June 2018

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 26 June 2018 PIL

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 15 January 2018

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 15 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 15 January 2018 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

4.4. Special warnings and precautions for use

6.1. List of excipients

Updated on 15 January 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 6 - what the product looks like and pack contents

Updated on 3 August 2017 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8. Undesirable effects

 

Updated on 1 August 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 17 August 2016 SPC

Reasons for updating

  • Removal of black triangle

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Removal of Black Triangle

Updated on 28 June 2016 PIL

Reasons for updating

  • Removal of black triangle

Updated on 14 December 2015 PIL

Reasons for updating

  • Change to further information section

Updated on 18 November 2015 SPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company



In section 5.2  (Preclinical safety data)

Chronic toxicity studies conducted by the oral route in dogs (5 to 40 mg.kg-1.d-1) and rats (5 to 200 mg.kg-1.d-1), showed a good safety profile.

Neither embryo-foetotoxic effects nor teratogenicity were detected in mice and in rabbits. The general study on reproduction and embryogenesis in 3 generations of rats showed no anomalies. The genotoxic potential was thoroughly assessed with three in vitro studies including the evaluation of the mutagenic and clastogenic potential and one in vivo study. All tests were negative.

 

 

 

Updated on 3 October 2014 PIL

Reasons for updating

  • Addition of information on reporting a side effect.
  • Addition of black triangle

Updated on 22 September 2014 SPC

Reasons for updating

  • Addition of black triangle
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

-Black triangle included with the following text "This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions."$0-In section 4.8 details for the reporting of suspected adverse reactions has been edited;$0"Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel:+353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie."

Updated on 18 February 2014 PIL

Reasons for updating

  • Addition of information on reporting a side effect.
  • Addition of black triangle

Updated on 10 February 2014 SPC

Reasons for updating

  • Addition of black triangle
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

$01. Addition of black triangle$0$0$0$02. section 4.8: addition of information regarding the reporting of suspected adverse reactions

Updated on 5 March 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to information about driving or using machinery
  • Change of contraindications
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration
  • Change to improve clarity and readability

Updated on 8 October 2012 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

$0Section 4.1 $0$0Change in indication: Vastarel 20mg is nowonly indicated in adultsas add-on therapy for the symptomatic treatment of patients with stable anginapectoris who are inadequately controlled by or intolerant to first-line anti-anginaltherapies. $0$0Section 4.2 $0$0The recommended dose is now statedas “one tablet of 20mg oftrimetazidine three times a day during meals. “ Specific information has been added ontrimetazidine use in patients with renal impairment, use in elderly patientsand in paediatric populations. $0$0Section 4.3$0$0Vastarel is now also contraindicatedin Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome,and other related movement disorders and in severe renal impairment (creatinineclearance < 30ml/min).$0$0Section 4.4 $0$0Special warnings have been addedregarding the occurrence of parkinsoniansymptoms and movements disorders and regarding the use of trimetazidine inpatients with moderate renal impairment and in elderly patients over the age of75 yrs.$0$0Section 4.7$0$0New information has been added regardingeffects on ability to drive anduse machines. $0$0Section 4.8 $0$0A table of undesirable effects has beencreated. Several new side effects have been added.$0$0Section 5.1$0$0Information has been added regarding mechanismof action, pharmacodynamic effects and clinical efficacy and safety.$0

Updated on 4 March 2011 SPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change in date of revision of text from September 2007 to January 2008

Updated on 3 December 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to how the medicine works
  • Change to date of revision
  • Change to improve clarity and readability
  • Change of special precautions for disposal

Updated on 18 February 2008 SPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes to sections 4.1, 4.4, 4.6 and 4.8

Updated on 5 June 2007 PIL

Reasons for updating

  • Change to date of revision

Updated on 5 June 2007 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Product Authorisation renewal in April 2007.

Updated on 20 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 11 June 2003 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)